Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Yorihiro IwasakiEndocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.ORCID 0000-0001-9787-7922
Monica ReyesEndocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
Anna Ryabets-LienhardCenter for Endocrinology, Diabetes, and Metabolism, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027.ORCID 0000-0001-7851-4069
Barbara GalesDepartment of Pediatrics, Division of Pediatric Nephrology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, CA 90095.
Agnès LinglartUniversité Paris-Saclay, INSERM, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre 94276, France.ORCID 0000-0003-3455-002X
Danny E MillerDivision of Genetic Medicine, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA 98195.ORCID 0000-0001-6096-8601
Isidro B SaluskyDepartment of Pediatrics, Division of Pediatric Nephrology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, CA 90095.
Murat BastepeEndocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.ORCID 0000-0002-2643-3504
Harald JüppnerEndocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.ORCID 0000-0001-7491-0515
Funding
PTH/PTHRP RECEPTOR DEFECTS IN PSEUDOHYPOPARATHYROIDISMR01DK046718 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI JUEPPNER, HARALD W. · 1993 to 2024
$6.0M
Skeletal FGF23 production mediated by GPCR/Gq/PKC signalingR01DK121776 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BASTEPE, MURAT · 2020 to 2024
$2.4M
Control of allelic Gsα expression for regulating hormone signalingR01DK140244 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MURAT BASTEPE · 2024 to 2026
$2.1M
Long-read DNA and RNA sequencing to identify disease-causing genetic variation and streamline testingDP5OD033357 · OD · UNIVERSITY OF WASHINGTON · PI MILLER, DANNY ERWIN · 2022 to 2025
$1.9M
Cell Science Research Foundation FellowshipHHS | National Institutes of Health (NIH) DP5OD033357HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK046718HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK121776HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK140244International Medical Research Foundation FellowshipJapan Society for the Promotion of Science London (JSPS) 19K20170NIDDK NIH HHS R01 DK046718NIDDK NIH HHS R01 DK121776NIDDK NIH HHS R01 DK140244NIH HHS DP5 OD033357Uehara Memorial Foundation (UMF) FellowshipYamada Science Foundation (YSF) Fellowship
6 · The paper itself
Abstract
Pseudohypoparathyroidism type 1B (PHP1B) is a multihormone resistance disorder caused by aberrant
Indexed as
ChromograninsDNA MethylationGTP-Binding Protein alpha Subunits, GsPseudohypoparathyroidismAnimalsEpigenesis, GeneticFemaleHumansMaleMiceRetroelementsSyntaxin 16ChromograninsGNAS protein, humanGTP-Binding Protein alpha Subunits, GsRetroelementsSTX16 protein, humanSyntaxin 16epigeneticsgenomic imprintingGNASpseudohypoparathyroidismretrotransposon
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Bidirectional disruption of · full record | OpenQuestion